1. American Society of Clinical Oncology (2015) Clinical trial designs for studying targeted therapies,
https://am.asco.org/clinical-trial-designs-studying-targeted-therapies
, accessed 20 October 2015.
2. Amery, W. and Dony, J. (1975) A clinical trial design avoiding undue placebo treatment. Journal of Clinical Pharmacology 15(10): 674–679.
3. Angst, M. (2013) Response to pharmacologic challenges in Phase 2 and Phase 3 trials [Power Point presentation]. Paper presented at the IMMPACT-XVI: Recommendations for patient phenotyping in Phase 2 and 3 analgesic clinical trials. 14-15 June, Washington DC.
4. Arthritis Research UK (2013) Analgesics in chronic non-cancer pain: Published trials using an enriched enrolment, randomised withdrawal (EERW) design,
http://www.arthritisresearchuk.org/research/research-funding-and-policy/our-clinical-study-groups/musculoskeletal-pain-disorders/reports-and-horizon-scanning.aspx
, accessed 26 June 2014.
5. Attall, N. et al (2011) Assessing symptom profiles in neuropathic pain clinical trials: Can it improve outcome? European Journal of Pain 15(5): 441–443.